Podium to Practice: Chicago 2025 – GU: CheckMate 901

OR
Please enter your username or email address. You will receive an email message to log in.
Explore more from your favourite experts – click their name to access their entire library of content.

Chair

Speakers
Studies / Trials Discussed
4500 – Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
This program has been made possible through unrestricted support from Ipsen.
Studies/trials discussed:
4500 – Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.